Valiant Organics Limited Q2 FY27 Revenue Doubles, PAT Hits ₹17 Crore
Key highlights
- Valiant Organics reported Q2 FY27 revenue of ₹304.22 crore, up 93.39% year-on-year.
- Net profit increased to ₹17.30 crore from ₹5.66 crore in Q2 FY26.
- EBITDA was ₹39.02 crore, while EBITDA margin declined to 12.83% from 17.98% in Q1 FY27.
- Earnings per share for Q2 FY27 stood at ₹6.18.
powered by IRIS

Valiant Organics Limited reported consolidated Q2 FY27 revenue of ₹304.22 crore, up 93.39% year-on-year, while net profit rose to ₹17.30 crore for the quarter ended September 30, 2026. The result shows a sharp recovery in sales and profit from the year-ago period, although profitability weakened sequentially as costs increased faster than revenue.
Know Valiant Organics inside out
Results, valuation, peers and who's buying, in one view.
What did Valiant Organics report in Q2 FY27?
Valiant Organics reported its highest quarterly revenue of ₹304.22 crore in Q2 FY27, compared with ₹157.31 crore in Q2 FY26 and ₹231.5 crore in Q1 FY27. Revenue therefore increased 93.39% year-on-year and 31.39% quarter-on-quarter. Total income was ₹305.33 crore, including other income of ₹1.11 crore.
The company posted profit before tax of ₹24.78 crore and net profit after tax of ₹17.30 crore. Basic and diluted earnings per share stood at ₹6.18. Net profit was substantially above the ₹5.66 crore reported in the corresponding quarter last year, but below the approximately ₹29.3 crore reported in the preceding quarter.
The board approved the unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The limited-review conclusion was unmodified, according to the reported filing summary. No earnings-call transcript for the quarter was published in the material provided, so the available figures reflect the results statement rather than management guidance.
Why did profit decline from the previous quarter?
Profit declined sequentially because the growth in operating expenses outpaced the rise in revenue. Revenue increased 31.39% from Q1 FY27, while reported expenses increased 39.64%, resulting in lower operating profitability despite the stronger sales base.
Operating profit, or EBITDA, was ₹39.02 crore in Q2 FY27, compared with ₹21.16 crore a year earlier. The EBITDA margin was 12.83%, below 17.98% in Q1 FY27, a sequential contraction of 515 basis points. This shows that the year-on-year revenue recovery was accompanied by near-term cost pressure.
Other income also fell from the preceding quarter, while profit before tax declined from about ₹36.8 crore in Q1 FY27 to ₹24.78 crore. The reported tax rate rose to 30.21%, which contributed to the sequential fall in net profit. Interest and depreciation were broadly stable sequentially at about ₹5 crore and ₹10 crore, respectively.
What are the key Q2 FY27 financial figures?
The key financial figures show strong year-on-year improvement in revenue, operating profit and net profit, alongside a weaker margin profile compared with Q1 FY27. The following table summarises the reported consolidated numbers.
The company reported revenue growth of 93.39% year-on-year, while net profit rose from ₹5.66 crore in Q2 FY26 to ₹17.30 crore. Operating profit also increased 84.4% from the year-ago quarter. These comparisons indicate a substantially stronger operating scale than in the corresponding period last year.
But quarter-on-quarter figures point to a different trend. EBITDA declined from around ₹42 crore despite higher revenue, and the margin fell to 12.83%. For investors, this distinction matters because sales growth alone did not translate into sequential growth in operating profit or net profit.
Got a follow-up? Ask IRIS
How does the quarter relate to Valiant Organics' business strategy?
Valiant Organics operates in benzene-based specialty chemical intermediates used in agrochemicals, pharmaceuticals, dyes, pigments and veterinary applications. It has six integrated manufacturing plants across five locations in western India, with approximately 80,000 MTPA of installed capacity and more than 900 employees, according to the company information provided.
The company has identified high demand and low supply in specialty chemicals, with several products dependent on imports. Its investor presentation also refers to a focus on higher-margin benzene and chlorophenol derivatives. This positioning links the company to import-substitution opportunities and demand from downstream chemical users.
Its FY26 presentation reported revenue of ₹739 crore and an EBITDA margin of 13.64%. The Q2 FY27 EBITDA margin of 12.83% was therefore below that FY26 level as well as below Q1 FY27. The reported numbers underline that product mix, input costs and operating expenses remain relevant to the earnings profile even when sales rise sharply.
What does the result mean for investors and the specialty chemicals sector?
The result gives investors two clear data points: revenue has recovered strongly from the year-ago quarter, but sequential margins and profit have weakened. Revenue rose by nearly ₹147 crore year-on-year, whereas net profit was lower by roughly ₹12 crore compared with Q1 FY27. This makes the sustainability of margins an important factor in assessing subsequent results.
For industry participants, the quarter reflects the differing effects of volume or sales expansion and cost movements in specialty chemicals. Valiant Organics serves multiple end-markets, including agrochemicals and pharmaceuticals, which can support demand diversity. However, the reported cost increase demonstrates that revenue expansion does not necessarily produce proportionate earnings growth in every quarter.
The company did not provide earnings-call guidance in the supplied material on future margins, orders or profitability. As a result, the published results provide evidence of current-quarter performance but do not establish a forecast for the next quarter.
Conclusion
Valiant Organics delivered a marked year-on-year improvement in Q2 FY27, with revenue of ₹304.22 crore and net profit of ₹17.30 crore. The stronger sales base and higher year-on-year operating profit show improved performance versus Q2 FY26, while the sequential decline in EBITDA margin and PAT shows that costs remained a material constraint.
The next results will indicate whether Valiant Organics can convert its higher revenue base into steadier operating margins. Investors will also watch for further disclosures on the company's higher-margin benzene and chlorophenol derivative focus, import-substitution opportunity and cost trends.


